Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caris Life Sciences (CAI) Treasury Shares (2024 - 2025)

Caris Life Sciences has reported Treasury Shares over the past 2 years, most recently at $16.9 million for Q4 2025.

  • Quarterly results put Treasury Shares at $16.9 million for Q4 2025, up 5020.0% from a year ago — trailing twelve months through Dec 2025 was $16.9 million (up 5020.0% YoY), and the annual figure for FY2025 was $16.9 million, up 5020.0%.
  • Treasury Shares for Q4 2025 was $16.9 million at Caris Life Sciences, roughly flat from $16.9 million in the prior quarter.
  • Over the last five years, Treasury Shares for CAI hit a ceiling of $4.4 million in Q3 2025 and a floor of $182500.0 in Q2 2024.